Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Pongo abelii Long-chain fatty acid transport protein 4 (SLC27A4), partial CSB-YP729076PYX1
CSB-EP729076PYX1
CSB-BP729076PYX1
CSB-MP729076PYX1
CSB-EP729076PYX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii UPF0485 protein C1orf144 homolog CSB-YP729077PYX
CSB-EP729077PYX
CSB-BP729077PYX
CSB-MP729077PYX
CSB-EP729077PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii 26S proteasome non-ATPase regulatory subunit 8 (PSMD8) CSB-YP729078PYX
CSB-EP729078PYX
CSB-BP729078PYX
CSB-MP729078PYX
CSB-EP729078PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Transmembrane emp24 domain-containing protein 10 (TMED10), partial CSB-YP729079PYX
CSB-EP729079PYX
CSB-BP729079PYX
CSB-MP729079PYX
CSB-EP729079PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Trichoplein keratin filament-binding protein (TCHP) CSB-YP729080PYX
CSB-EP729080PYX
CSB-BP729080PYX
CSB-MP729080PYX
CSB-EP729080PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Sodium-coupled neutral amino acid transporter 4 (SLC38A4), partial CSB-YP729081PYX
CSB-EP729081PYX
CSB-BP729081PYX
CSB-MP729081PYX
CSB-EP729081PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Aspartate aminotransferase, mitochondrial (GOT2) CSB-YP729082PYX
CSB-EP729082PYX
CSB-BP729082PYX
CSB-MP729082PYX
CSB-EP729082PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Zinc finger C2HC domain-containing protein 1A (ZC2HC1A) CSB-YP729083PYX
CSB-EP729083PYX
CSB-BP729083PYX
CSB-MP729083PYX
CSB-EP729083PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii U3 small nucleolar RNA-associated protein 15 homolog (UTP15), partial CSB-YP729084PYX
CSB-EP729084PYX
CSB-BP729084PYX
CSB-MP729084PYX
CSB-EP729084PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Squamous cell carcinoma antigen recognized by T-cells 3 (SART3), partial CSB-YP729085PYX
CSB-EP729085PYX
CSB-BP729085PYX
CSB-MP729085PYX
CSB-EP729085PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Probable palmitoyltransferase ZDHHC6 (ZDHHC6), partial CSB-YP729086PYX1
CSB-EP729086PYX1
CSB-BP729086PYX1
CSB-MP729086PYX1
CSB-EP729086PYX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Anaphase-promoting complex subunit 16 (ANAPC16) CSB-YP729087PYX
CSB-EP729087PYX
CSB-BP729087PYX
CSB-MP729087PYX
CSB-EP729087PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Dimethylaniline monooxygenase [N-oxide-forming] 2 (FMO2), partial CSB-YP729088PYX
CSB-EP729088PYX
CSB-BP729088PYX
CSB-MP729088PYX
CSB-EP729088PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Leukocyte surface antigen CD47 (CD47), partial CSB-YP729089PYX1
CSB-EP729089PYX1
CSB-BP729089PYX1
CSB-MP729089PYX1
CSB-EP729089PYX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Leydig cell tumor 10 kDa protein homolog CSB-YP729090PYX
CSB-EP729090PYX
CSB-BP729090PYX
CSB-MP729090PYX
CSB-EP729090PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A (MGAT4A), partial CSB-YP729091PYX
CSB-EP729091PYX
CSB-BP729091PYX
CSB-MP729091PYX
CSB-EP729091PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Hyaluronidase-3 (HYAL3) CSB-YP729092PYX
CSB-EP729092PYX
CSB-BP729092PYX
CSB-MP729092PYX
CSB-EP729092PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii 3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) CSB-YP729093PYX
CSB-EP729093PYX
CSB-BP729093PYX
CSB-MP729093PYX
CSB-EP729093PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii ADP-ribosylation factor-like protein 4D (ARL4D) CSB-YP729094PYX
CSB-EP729094PYX
CSB-BP729094PYX
CSB-MP729094PYX
CSB-EP729094PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2 (PPIP5K2), partial CSB-YP729095PYX
CSB-EP729095PYX
CSB-BP729095PYX
CSB-MP729095PYX
CSB-EP729095PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>